Comparison of Allergic Adverse Effect and Contrast Enhancement of Iodixanol (Visipaque) and Iopromide (Ultravist)

Background/Objective: This study was carried"nout to compare allergic adverse effect and contrast"nenhancement of visipaque versus ultravist."nPatients and Methods: One-hundred twenty patients"nwho were referred for CT scan of the abdomen were"nincluded in this study. Patients were randomly divided"ninto two groups (group A and B) of which group A"nreceived 100 cc iodixanol (visipaque 300 mgI/ml) and"ngroup B received 100 cc iopromide (300 mgI/ml) by"na power injector CT examination was obtained with"nSoma tom helical CT scanner ( Siemens, Germany)."n60 seconds after injection images were obtained and"nenhancement of the portal vein, liver and aorta were"ndetermined. Allergic adverse effects were recorded 1"nhour and up to one week after injection"nResults: Visipaque produced significantly greater"nenhancement of the liver, aorta and portal vein than"niopromide 60 seconds after injection (97.9 HU, 157.8"nHU and 131.5 HU versus 86.9 HU, 143.9 and 119.8 HU,"nrespectively) these values were statistically significant"n(p<0.01). Injection associated pain and heat sensation"nwas less frequent in visipaque in comparison with"nultravist (p=0.03). Immediate reactions such as nausea"nand vomiting was less frequent in visipaque (p=0.01)."nRegarding late skin reaction, skin reaction such as rash"nwas more frequent in visipaque (p<0.01)"nConclusion: Iodixanol (visipaque) is safe and is better"ntolerated in the early phase of injection with better"ncontrast enhancement and lesion conspicuity, but it"nmay causre mild skin rash."nKeywords: Iodixanol, Iopromide, Contrast"nEnhancement, Allergic Adverse Effect